PRSS2

Summary

PRSS2 (serine protease 2, HGNC:9483) is a protein-coding gene on chromosome 7q34, encoding Trypsin-2 (P07478). In the ileum, may be involved in defensin processing, including DEFA5.

This gene belongs to the trypsin family of serine proteases and encodes anionic trypsinogen. It is part of a cluster of trypsinogen genes that are located within the T cell receptor beta locus. Enzymes of this family cleave peptide bonds that follow lysine or arginine residues. This protein is found at high levels in pancreatic juice and its upregulation is a characteristic feature of pancreatitis. This protein has also been found to activate pro-urokinase in ovarian tumors, suggesting a function in tumor invasion. In addition, this enzyme is able to cleave across the type II collagen triple helix in rheumatoid arthritis synovitis tissue, potentially participating in the degradation of type II collagen-rich cartilage matrix. Alternative splicing results in multiple transcript variants.

Source: NCBI Gene 5645 — RefSeq curated summary.

At a glance

• GWAS associations: 1
• Clinical variants (ClinVar): 2 total
• GTEx eGene: eQTL in 5 tissues, sQTL in 0 (q < 0.05)
• Phenotypes (HPO): 17
• ChEMBL bioactivity: 12 clinical-phase molecules tested; no curated mechanism-of-action drug
• Constraint (gnomAD): pLI 0.00 (LoF-tolerant), LOEUF 1.59 (unconstrained)
• MANE Select transcript: NM_002770

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:9483
Approved symbol	PRSS2
Name	serine protease 2
Location	7q34
Locus type	gene with protein product
Status	Approved
Aliases	TRY2
Ensembl gene	ENSG00000275896
Ensembl biotype	protein_coding
OMIM	601564
Entrez	5645

Gene structure

Transcript identifiers

Ensembl transcripts: 6 — 4 protein_coding, 1 retained_intron, 1 protein_coding_CDS_not_defined

MANE Select: ENST00000539842

Transcript support level (Ensembl TSL; 1 = fully mRNA-supported): TSL 1: 3, TSL 2: 2

ENST00000539842, ENST00000610835, ENST00000618750, ENST00000632998, ENST00000633969, ENST00001136148

RefSeq mRNA: 2 — MANE Select: NM_002770 NM_001303414, NM_002770

CCDS: CCDS83235, CCDS83236

Canonical transcript exons

ENST00000539842 — 5 exons

Exon	Start	End
ENSE00002507173	142774356	142774560
ENSE00003721434	142772049	142772208
ENSE00003736987	142773919	142774055
ENSE00003753318	142770970	142771022
ENSE00003783126	142773266	142773519

Expression profiles

Bgee: expression breadth ubiquitous, 125 present calls, max score 100.00.

FANTOM5 (CAGE): breadth tissue_specific, TPM avg 43.5792 / max 75717.6810, expressed in 35 samples.

Highest expression (Bgee): body of pancreas, pancreas, islet of Langerhans, duodenum, small intestine Peyer’s patch.

Genetic regulation across tissues (GTEx eQTL / sQTL)

PRSS2 is an eGene in GTEx v10 — its expression is genetically regulated (eQTL) in 5 tissues and its splicing (sQTL) in 0 (q < 0.05). Strongest associations first; slope = normalized effect of the lead variant’s alternative allele.

5 significant tissue × QTL associations:

Tissue	QTL	q-value	Slope	Lead variant
Pancreas	eqtl	2.8e-07	+0.29	7:142800425:T:C
Heart Atrial Appendage	eqtl	7.4e-03	+0.98	7:142557058:A:C
Spleen	eqtl	4.5e-02	+0.35	7:142605391:C:T
Nerve Tibial	eqtl	4.8e-02	-0.20	7:142050672:A:G
Skin Sun Exposed Lower leg	eqtl	4.9e-02	+0.40	7:142680963:A:C

FANTOM5 promoters

showing 10 of 12 alternative TSS:

Promoter ID	TPM avg	Samples expressed
204926	559.2093	239
81640	43.5792	35
204927	0.6996	7
204932	0.5660	6
204925	0.3121	20
204924	0.1450	17
204929	0.1053	4
204928	0.1007	3
204930	0.0372	2
204922	0.0362	2

Top tissues by expression

showing 100 of 134 tissues by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
body of pancreas	UBERON:0001150	100.00	gold quality
pancreas	UBERON:0001264	99.98	gold quality
islet of Langerhans	UBERON:0000006	99.94	gold quality
duodenum	UBERON:0002114	99.48	gold quality
small intestine Peyer’s patch	UBERON:0003454	96.48	gold quality
small intestine	UBERON:0002108	95.72	gold quality
male germ line stem cell (sensu Vertebrata) in testis	CL:0000089 ∩ UBERON:0000473	93.23	gold quality
fundus of stomach	UBERON:0001160	89.62	gold quality
ectocervix	UBERON:0012249	89.31	gold quality
right coronary artery	UBERON:0001625	88.57	gold quality
body of stomach	UBERON:0001161	88.26	gold quality
lower esophagus mucosa	UBERON:0035834	87.71	gold quality
endocervix	UBERON:0000458	87.55	gold quality
right uterine tube	UBERON:0001302	87.53	gold quality
left uterine tube	UBERON:0001303	87.47	gold quality
right adrenal gland	UBERON:0001233	85.91	gold quality
right lobe of liver	UBERON:0001114	85.53	gold quality
right adrenal gland cortex	UBERON:0035827	84.88	gold quality
stomach	UBERON:0000945	83.68	gold quality
mucosa of stomach	UBERON:0001199	82.82	gold quality
descending thoracic aorta	UBERON:0002345	81.78	gold quality
left ovary	UBERON:0002119	79.52	gold quality
uterine cervix	UBERON:0000002	79.48	gold quality
right ovary	UBERON:0002118	79.30	gold quality
spleen	UBERON:0002106	79.04	gold quality
esophagus mucosa	UBERON:0002469	78.76	gold quality
left adrenal gland	UBERON:0001234	78.34	gold quality
intestine	UBERON:0000160	78.21	gold quality
body of uterus	UBERON:0009853	78.16	gold quality
apex of heart	UBERON:0002098	77.82	gold quality
ovary	UBERON:0000992	77.74	gold quality
transverse colon	UBERON:0001157	77.71	gold quality
left adrenal gland cortex	UBERON:0035825	77.09	gold quality
thoracic aorta	UBERON:0001515	76.78	gold quality
metanephros cortex	UBERON:0010533	76.73	gold quality
right hemisphere of cerebellum	UBERON:0014890	75.97	gold quality
ascending aorta	UBERON:0001496	75.79	gold quality
vastus lateralis	UBERON:0001379	75.44	gold quality
esophagus	UBERON:0001043	75.34	gold quality
urinary bladder	UBERON:0001255	74.96	gold quality
placenta	UBERON:0001987	74.35	gold quality
lower esophagus	UBERON:0013473	73.82	gold quality
lower esophagus muscularis layer	UBERON:0035833	73.59	gold quality
vagina	UBERON:0000996	73.11	gold quality
colon	UBERON:0001155	72.79	gold quality
fallopian tube	UBERON:0003889	72.68	gold quality
thoracic mammary gland	UBERON:0005200	72.10	gold quality
prostate gland	UBERON:0002367	72.07	gold quality
saliva-secreting gland	UBERON:0001044	71.94	gold quality
omental fat pad	UBERON:0010414	71.08	gold quality
muscle layer of sigmoid colon	UBERON:0035805	70.79	gold quality
pituitary gland	UBERON:0000007	70.78	gold quality
right lobe of thyroid gland	UBERON:0001119	70.69	gold quality
esophagogastric junction muscularis propria	UBERON:0035841	70.50	gold quality
minor salivary gland	UBERON:0001830	69.93	gold quality
adrenal gland	UBERON:0002369	69.92	gold quality
cerebellar hemisphere	UBERON:0002245	69.79	gold quality
mucosa of transverse colon	UBERON:0004991	69.67	gold quality
cerebellar cortex	UBERON:0002129	69.04	gold quality
cerebellum	UBERON:0002037	68.87	gold quality
left testis	UBERON:0004533	68.78	gold quality
right atrium auricular region	UBERON:0006631	68.62	gold quality
left coronary artery	UBERON:0001626	66.71	gold quality
right frontal lobe	UBERON:0002810	65.80	gold quality
myometrium	UBERON:0001296	65.62	gold quality
multicellular organism	UBERON:0000468	65.49	gold quality
skin of abdomen	UBERON:0001416	65.34	gold quality
tibial artery	UBERON:0007610	65.21	gold quality
popliteal artery	UBERON:0002250	64.92	gold quality
testis	UBERON:0000473	64.66	gold quality
adipose tissue	UBERON:0001013	64.65	gold quality
blood	UBERON:0000178	64.52	gold quality
right testis	UBERON:0004534	64.09	gold quality
left lobe of thyroid gland	UBERON:0001120	63.75	gold quality
zone of skin	UBERON:0000014	63.54	gold quality
adenohypophysis	UBERON:0002196	63.34	gold quality
heart	UBERON:0000948	63.10	gold quality
skin of leg	UBERON:0001511	62.78	gold quality
heart left ventricle	UBERON:0002084	62.66	gold quality
upper lobe of left lung	UBERON:0008952	62.32	gold quality
gastrocnemius	UBERON:0001388	62.28	gold quality
vermiform appendix	UBERON:0001154	62.19	gold quality
Ammon’s horn	UBERON:0001954	61.99	gold quality
thyroid gland	UBERON:0002046	61.64	gold quality
anterior cingulate cortex	UBERON:0009835	61.54	gold quality
subcutaneous adipose tissue	UBERON:0002190	59.85	gold quality
tibial nerve	UBERON:0001323	58.98	gold quality
liver	UBERON:0002107	58.83	gold quality
adult mammalian kidney	UBERON:0000082	58.58	gold quality
amygdala	UBERON:0001876	58.12	gold quality
temporal lobe	UBERON:0001871	57.68	gold quality
muscle of leg	UBERON:0001383	56.80	gold quality
bone marrow	UBERON:0002371	56.15	gold quality
lymph node	UBERON:0000029	55.13	gold quality
brain	UBERON:0000955	55.00	gold quality
hypothalamus	UBERON:0001898	54.73	gold quality
putamen	UBERON:0001874	54.34	gold quality
lung	UBERON:0002048	53.69	gold quality
kidney	UBERON:0002113	53.43	gold quality
substantia nigra	UBERON:0002038	52.96	gold quality

Single-cell (SCXA)

Detected in 14 experiment(s), a significant marker in 13.

Experiment	Marker?	Max mean expression
E-GEOD-81547	yes	72979.27
E-ENAD-27	yes	21135.44
E-MTAB-5061	yes	19349.34
E-HCAD-31	yes	19051.09
E-GEOD-83139	yes	14918.53
E-CURD-46	yes	13311.91
E-GEOD-76312	yes	2362.67
E-MTAB-8207	yes	869.05
E-MTAB-7407	yes	588.32
E-MTAB-10283	yes	301.24
E-HCAD-6	yes	220.00
E-CURD-98	yes	165.89
E-GEOD-100618	no	7631.26
E-ANND-3	no	0.00

HPA expression

RNA tissue specificity: Tissue enriched

39 HPA tissues / cells by nTPM:

Tissue / cell	Axis	nTPM	Protein (IHC)
Pancreas	tissue	138427.8	high
Small intestine	tissue	497.7	high
Duodenum	tissue	336.5	high
Ovary	tissue	26.7	not detected
Salivary gland	tissue	23.8	not detected
Heart muscle	tissue	23.5	not detected
Stomach 1	tissue	23.0	not detected
Pituitary gland	tissue	12.1
Vagina	tissue	9.5	not detected
Placenta	tissue	7.6	not detected
Bone marrow	tissue	3.0	not detected
Skin 1	tissue	2.9	not detected
Adipose tissue	tissue	2.3	not detected
Endometrium 1	tissue	1.5	not detected
Lymph node	tissue	1.2	not detected
Seminal vesicle	tissue	0.9	not detected
Spleen	tissue	0.9	not detected
Thymus	tissue	0.8
Urinary bladder	tissue	0.7	not detected
Fallopian tube	tissue	0.7	not detected
Kidney	tissue	0.6	not detected
Basal ganglia	tissue	0.5	not detected
Putamen	tissue	0.5
Cerebral cortex	tissue	0.4	not detected
Lung	tissue	0.4	not detected
Colon	tissue	0.3	not detected
Nucleus accumbens	tissue	0.3
Amygdala	tissue	0.2
Appendix	tissue	0.2	not detected
Occipital cortex	tissue	0.2
Testis	tissue	0.1	not detected
Esophagus	tissue	0.1	not detected
Smooth muscle	tissue	0.1	not detected
Medulla oblongata	tissue	0.1
Thalamus	tissue	0.1
Hypothalamus	tissue	0.1
Gallbladder	tissue	0.1	not detected
Hippocampal formation	tissue	0.1
Retrosplenial cortex	tissue	0.1

Brain sub-regions (HPA Brain Atlas): detected in 64; highest nTPM — Blood vessel (60.9), Caudate nucleus (0.4), Fusiform gyrus (0.4), Nucleus basalis of Meynert (0.4), Middle temporal gyrus (0.3).

Regulation

Is transcription factor: no

Functional genomics

gnomAD constraint: pLI 2.64e-07, LOEUF 1.59, missense Z -1.29 — population loss-of-function intolerance (pLI ≥ 0.9 = LoF-intolerant; lower LOEUF = more constrained). gnomAD

Regional missense constraint (gnomAD RMC): no regional variation along ENST00000539842 — one region, missense o/e 0.98.

Literature-anchored findings (GeneRIF, showing 38)

• Results indicate that up-regulation of anionic trypsinogen in pancreatic diseases does not affect physiological trypsinogen activation, but significantly limits trypsin generation under potential pathological conditions. (PMID:12709065)
• High levels of pulmonary trypsin-2 may be associated with the development of bronchopulmonary dysplasia in preterm infants. (PMID:12949286)
• pancreatitis-associated cationic trypsin mutations causes increased transactivation of anionic trypsinogen. (PMID:14695529)
• Expression of trypsinogen 1 and 2 is better preserved than prostate specific antigen in high-grade prostatic neoplasms (PMID:15651064)
• gene conversion between PRSS1 and PRSS2 trypsinogen genes can occur and cause genetically determined chronic pancreatitis (PMID:15776435)
• G191R variant of PRSS2 mitigates intrapancreatic trypsin activity and thereby protects against chronic pancreatitis (PMID:16699518)
• Our results suggest that serum trypsinogen-2 is a most useful marker for diagnosing patients with cholangiocarcinoma, and it is superior to serum CA19-9 and CEA. (PMID:17640760)
• Co-localization of trypsin-2 and MMP-9 resulted in intracellular proMMP-9 processing that represented fully or partially activated MMP-9. (PMID:18062964)
• A loss of function polymorphism (G191R) of anionic trypsinogen (PRSS2) confers protection against chronic pancreatitis. (PMID:18362849)
• Total immunoreactivity of soluble urinary MMP-14 and the levels of trypsin (TRY)-1 and TRY-2, but not of TATI, were also significantly increased in diabetic nephropathy (PMID:18428024)
• A fusion with PRSS1 is associated with hereditary pancreatitis. (PMID:18461367)
• primary role of trypsinogen sulfation in humans is to stimulate autoactivation of PRSS1 (PMID:18986305)
• The p.G191R variant protected against alcoholic and idiopathic chronic pancreatitis as well as alcoholic acute pancreatitis in Japan. (PMID:19052022)
• G191R PRSS2 is a rare allele in the Indian population and the data suggest a nonsignificant trend towards a protective effect from tropical calcific pancreatitis in Indians. (PMID:19077465)
• Results do not support the urinary trypsinogen-2 dipstick test (UTDT) to replace standard plasma amylase for the diagnosis of AP, however, the test demonstrated an adequate sensitivity to be used for rapid early screening of AP in daily clinics. (PMID:19752771)
• Hyperexpression of the PRSS2 gene is associated with pancreatic cancer. (PMID:20428826)
• there was a borderline statistically significant association between pancreatic cancer and HAT/HCT but no association between pancreatic cancer and HAT, HCT. (PMID:20484960)
• Urine trypsinogen-2 test may be an important diagnostic tool in excluding the diagnosis of acute pancreatitis; it has a negative predictive value. (PMID:20517765)
• A genetic variant of PRSS2 may contribute to the low prevalence of pancreatitis in primary hyperparathyroidism patients. (PMID:20625975)
• results suggest that trypsinogen-2 is a more sensitive marker than amylase, and it can be useful in early diagnosis of post-endoscopic retrograde cholangiopancreatography (ERCP) pancreatitis. (PMID:21792081)
• Data show that urinary trypsinogen-2 dipstick test is a useful test for early diagnosis of post-endoscopic retrograde cholangiopancreatography (ERCP) pancreatitis. (PMID:21946810)
• Elevation of urine trypsinogen 2 is an independent risk factor for pancreatic fistula after pancreaticoduodenectomy. (PMID:22357509)
• Report a simple, rapid, easy, and noninvasive urinary trypsinogen-2 test can diagnose or rule out most cases of acute pancreatitis. (PMID:22481290)
• trypsin-2 over-expression enhanced tongue carcinoma cell invasion by various genetic and proteolytic mechanisms. (PMID:22909050)
• Two associations with alcoholic pancreatitis at genome-wide significance were identified and replicated at PRSS1-PRSS2 and X-linked CLDN2 through a two-stage genome-wide study. (PMID:23143602)
• Trypsin-1 and trypsin-2 appear to have a function in the degradation of vitreous type II collagen. (PMID:23882137)
• PRSS2 single nucleotide polymorphism associated with the development of alcoholic pancreatitis. (PMID:25253127)
• Serum trypsinogen-2 is associated with pancreatic cancer and pancreatitis. (PMID:25916077)
• evaluated the association of claudin2 and PRSS1-PRSS2 polymorphisms with idiopathic recurrent acute (RAP) and chronic pancreatitis (PMID:26110235)
• Data indicate association between polymorphism rs10273639 of the PRSS1-PRSS2 locus and pancreatitis development. (PMID:27846138)
• Role of the Common PRSS1-PRSS2 Haplotype in Alcoholic and Non-Alcoholic Chronic Pancreatitis: Meta- and Re-Analyses. (PMID:33202925)
• Defective binding of SPINK1 variants is an uncommon mechanism for impaired trypsin inhibition in chronic pancreatitis. (PMID:33515547)
• TATI, TAT-2, and CRP as Prognostic Factors in Colorectal Cancer. (PMID:34794144)
• Trypsinogen (PRSS1 and PRSS2) gene dosage correlates with pancreatitis risk across genetic and transgenic studies: a systematic review and re-analysis. (PMID:35089416)
• Pancreatitis-Associated PRSS1-PRSS2 Haplotype Alters T-Cell Receptor Beta (TRB) Repertoire More Strongly Than PRSS1 Expression. (PMID:36191639)
• PRSS2 remodels the tumor microenvironment via repression of Tsp1 to stimulate tumor growth and progression. (PMID:36575174)
• High expression of serine protease 2 (PRSS2) associated with invasion, metastasis, and proliferation in gastric cancer. (PMID:37022096)
• PRSS2 regulates EMT and metastasis via MMP-9 in gastric cancer. (PMID:37331089)

Cross-species orthologs

16 orthologs

Organism	Symbol	Gene ID
danio_rerio	prss1	ENSDARG00000042993
mus_musculus	Try5	ENSMUSG00000036938
mus_musculus	Try4	ENSMUSG00000054106
mus_musculus	Prss2	ENSMUSG00000057163
mus_musculus	Prss1l	ENSMUSG00000058119
mus_musculus	Prss1	ENSMUSG00000062751
mus_musculus	Prss3l	ENSMUSG00000071517
mus_musculus	Prss3	ENSMUSG00000071519
mus_musculus	Try10	ENSMUSG00000071521
rattus_norvegicus	Prss2l1	ENSRNOG00000050493
rattus_norvegicus	Prss1	ENSRNOG00000063605
rattus_norvegicus	Prss2	ENSRNOG00000064731
rattus_norvegicus	Try10	ENSRNOG00000070336
rattus_norvegicus	LOC102554637	ENSRNOG00000075892
rattus_norvegicus	Prss3	ENSRNOG00000078399
rattus_norvegicus	Try5	ENSRNOG00000089144

Paralogs (3): PRSS3 (ENSG00000010438), PLAU (ENSG00000122861), PRSS1 (ENSG00000204983)

Mouse-model phenotypes

Observed phenotypes of the mouse ortholog (MGI:102759) from MGI (Alliance of Genome Resources) — knockout/mutant phenotypes, ranked by annotation count. 7 distinct phenotype terms.

Mouse phenotype (MP)	Records
decreased bone mineral density	1
decreased circulating phosphate level	1
increased exploration in new environment	1
limb grasping	1
impaired righting response	1
abnormal coat/hair pigmentation	1
decreased bone mineral content	1

Additional cross-species homologs

Sequence homologs in species beyond Ensembl Compara’s model organisms, by Diamond local protein alignment (% sequence identity; best hit per species). Lower-identity rows are more distant homologs. The matched accessions’ gene symbols aren’t in biobtree yet, so each row shows the UniProt accession.

Organism	UniProt	Identity	Method
Drosophila melanogaster	C0HKA2	100.0%	Diamond
Drosophila erecta	C0HKA5	100.0%	Diamond
Phytophthora sojae strain P6497	G5AE35	100.0%	Diamond
Macaca mulatta	P33619	99.2%	Diamond
Macaca fascicularis	Q6DT45	99.2%	Diamond
Pan troglodytes	Q2F9P2	98.7%	Diamond
Pan paniscus	Q2F9P4	98.7%	Diamond
Glossina austeni	Q4TTV7	98.2%	Diamond
Blarina brevicauda	Q5FBW1	98.2%	Diamond
Salmo salar	P35031	97.8%	Diamond
Papio hamadryas	Q28773	96.9%	Diamond
Bos taurus	P00741	96.8%	Diamond
Ovis aries	P16291	96.8%	Diamond
Gadus morhua	P16049	96.7%	Diamond
Manduca sexta	P35045	96.1%	Diamond
Vespa orientalis	P00768	95.4%	Diamond
Vespa crabro	P00769	95.4%	Diamond
Penaeus vannamei	P36178	94.5%	Diamond
Saguinus oedipus	Q7JIG6	93.4%	Diamond
Lucilia cuprina	P35043	91.5%	Diamond
Anopheles gambiae	Q17025	88.8%	Diamond
Canis lupus familiaris	P19540	88.5%	Diamond
Felis catus	Q6SA95	88.5%	Diamond
Sus scrofa	P51779	86.9%	Diamond
Oryctolagus cuniculus	Q28661	86.3%	Diamond

Genomic neighbors (locus context)

Genes flanking this one on the chromosome (NCBI/Entrez gene neighborhood). Positional context only — some neighbors share regulatory elements (bidirectional promoters, antisense/overlapping transcripts), but chromosomal adjacency is not itself a functional relationship (see Interactions for that).

Symbol	Type	Entrez
TRB	protein-coding	6957
PRSS1	protein-coding	5644
MIR11400	ncRNA	113839523
EPHB6	protein-coding	2051

Protein

Protein identifiers

Trypsin-2 — P07478 (reviewed: P07478)

Alternative names: Anionic trypsinogen, Serine protease 2, Trypsin II

All UniProt accessions (4): A0A0J9YYC8, A6XMV9, P07478, Q5NV56

UniProt curated annotations — full annotation on UniProt →

Function. In the ileum, may be involved in defensin processing, including DEFA5.

Subcellular location. Secreted. Extracellular space.

Tissue specificity. Expressed in Paneth cells, at the base of small intestinal crypts.

Post-translational modifications. Sulfated on tyrosine. Sulfation at Tyr-154 increases selectivity towards basic versus apolar residues at the P2’ position of inhibitors that bind in a substrate-like fashion. Although the increase in selectivity is relatively small, it may facilitate digestion of a broader range of dietary proteins.

Cofactor. Binds 1 Ca(2+) ion per subunit.

Polymorphism. His-153 variation is a common polymorphism in African populations with a minor allele frequency of 9.2%, it eliminates sulfation at Tyr-154, with no consequences on digestive physiology.

Similarity. Belongs to the peptidase S1 family.

RefSeq proteins (2): NP_001290343, NP_002761* (*=MANE)

Domains & families (InterPro)

ID	Name	Type
IPR001254	Trypsin_dom	Domain
IPR001314	Peptidase_S1A	Family
IPR009003	Peptidase_S1_PA	Homologous_superfamily
IPR018114	TRYPSIN_HIS	Active_site
IPR033116	TRYPSIN_SER	Active_site
IPR043504
IPR050127	Serine_Proteases_S1	Family

Pfam: PF00089

UniProt features (39 total): strand 14, binding site 4, disulfide bond 4, helix 4, active site 3, sequence variant 2, turn 2, signal peptide 1, propeptide 1, site 1, modified residue 1, chain 1, domain 1

Structure

Experimental structures (PDB)

1 structures by resolution:

PDB	Title	Method	Resolution (Å)
7Z9F	Human anionic trypsin after autoproteolysis at Arg122	X-RAY DIFFRACTION	1.7

Predicted structure (AlphaFold)

Model	pLDDT	Fraction very-high
AF-P07478-F1	92.17	0.86

Human Protein Atlas

Protein class: Enzymes, ENZYME proteins, Hydrolases, Peptidases, Serine-type peptidases, Predicted secreted proteins, Plasma proteins, Human disease related genes

Protein evidence: Evidence at protein level

Subcellular location (HPA, imaging): vesicles; endoplasmic reticulum

Antibody reliability (HPA): IH supported · IF approved

Functional residue map

Curated UniProt residues grouped by drug-discovery relevance — catalytic, ligand-binding, modification, and mutation-validated positions. Source: UniProtKB sequence features.

Catalytic / active sites (4)

Position	Role
194	required for specificity
63	charge relay system
107	charge relay system
200	charge relay system

Ligand- & substrate-binding residues (4)

Position	Role
85	Ca(2+)
75	Ca(2+)
77	Ca(2+)
80	Ca(2+)

Post-translational modifications (1)

Type	Positions
Sulfotyrosine	154

Disulfide bonds (4)

Type	Positions
Disulfide bond	30–160, 48–64, 171–185, 196–220

Function

Pathways and Gene Ontology

Reactome pathways

5 curated (TAS) of 10; 0 disease pathways. Curated-first; evidence = TAS (manually curated) vs IEA (electronic inference).

10 pathways:

ID	Pathway	Evidence
R-HSA-1592389	Activation of Matrix Metalloproteinases	curated
R-HSA-1462054	Alpha-defensins	curated
R-HSA-6803157	Antimicrobial peptides	curated
R-HSA-1442490	Collagen degradation	curated
R-HSA-6798695	Neutrophil degranulation	curated
R-HSA-1461973	Defensins	—
R-HSA-1474228	Degradation of the extracellular matrix	—
R-HSA-1474244	Extracellular matrix organization	—
R-HSA-168256	Immune System	—
R-HSA-168249	Innate Immune System	—

MSigDB gene sets: 165 (showing top): MODULE_172, GOBP_DIGESTION, MODULE_52, MODULE_92, REACTOME_INNATE_IMMUNE_SYSTEM, GOBP_ANTIMICROBIAL_HUMORAL_RESPONSE, GOMF_METALLOPEPTIDASE_ACTIVITY, GOCC_SECRETORY_GRANULE, GOBP_GROWTH, GOBP_POSITIVE_REGULATION_OF_CELL_ADHESION, MODULE_66, MODULE_118, BYSTRYKH_HEMATOPOIESIS_STEM_CELL_RUNX1, GOBP_DEFENSE_RESPONSE_TO_OTHER_ORGANISM, GAZDA_DIAMOND_BLACKFAN_ANEMIA_PROGENITOR_DN

GO Biological Process (7): proteolysis (GO:0006508), digestion (GO:0007586), antimicrobial humoral response (GO:0019730), extracellular matrix disassembly (GO:0022617), positive regulation of cell growth (GO:0030307), collagen catabolic process (GO:0030574), positive regulation of cell adhesion (GO:0045785)

GO Molecular Function (8): metalloendopeptidase activity (GO:0004222), serine-type endopeptidase activity (GO:0004252), calcium ion binding (GO:0005509), serine-type peptidase activity (GO:0008236), protein binding (GO:0005515), peptidase activity (GO:0008233), hydrolase activity (GO:0016787), metal ion binding (GO:0046872)

GO Cellular Component (3): extracellular region (GO:0005576), extracellular matrix (GO:0031012), azurophil granule lumen (GO:0035578)

Reactome top-level categories

6 top-level categories:

Category	Pathways
Degradation of the extracellular matrix	2
Innate Immune System	2
Defensins	1
Antimicrobial peptides	1
Extracellular matrix organization	1
Immune System	1

GO top-level categories

30 GO namespaces:

Category	Terms
positive regulation of cellular process	2
endopeptidase activity	2
protein metabolic process	1
multicellular organismal process	1
humoral immune response	1
defense response to symbiont	1
cellular component disassembly	1
extracellular matrix organization	1
regulation of cell growth	1
cell growth	1
positive regulation of growth	1
catabolic process	1
collagen metabolic process	1
cell adhesion	1
regulation of cell adhesion	1
metallopeptidase activity	1
serine-type peptidase activity	1
metal ion binding	1
peptidase activity	1
serine hydrolase activity	1
binding	1
hydrolase activity	1
catalytic activity, acting on a protein	1
catalytic activity	1
cation binding	1
cellular anatomical structure	1
external encapsulating structure	1
vacuolar lumen	1
secretory granule lumen	1
azurophil granule	1

Experimentally-supported GO annotations

GO terms backed by direct experimental evidence (ECO experimental codes) — 5 of 19 annotations. The rest are phylogenetic / computational / electronic (IEA).

5 experimentally-supported GO terms:

GO term	NS	Evidence
collagen catabolic process	BP	direct assay
proteolysis	BP	direct assay
extracellular region	CC	direct assay
calcium ion binding	MF	direct assay
serine-type endopeptidase activity	MF	direct assay

Protein interactions and networks

STRING

showing 15 of 702 interactions by confidence (×1000):

Protein A	Protein B	Partner UniProt	Score
PRSS2	SPINK1	P00995	929
PRSS2	MBL2	P11226	777
PRSS2	CFTR	P13569	700
PRSS2	HTRA1	Q92743	618
PRSS2	CPA1	P15085	608
PRSS2	ACE2	Q9BYF1	597
PRSS2	MORC4	Q8TE76	568
PRSS2	CPA2	P48052	542
PRSS2	STATH	P02808	519
PRSS2	FURIN	P09958	483
PRSS2	CPB1	P15086	464
PRSS2	COLEC11	Q9BWP8	425
PRSS2	CLDN2	P57739	420
PRSS2	CTSL	P07711	404
PRSS2	FCN2	Q15485	388

IntAct

Human interaction partners of PRSS2 in IntAct, one row per partner (best MIscore; records = supporting IntAct interaction records).

10 partners by confidence:

Partner	Interaction type	MIscore	Records
SLC35A2	physical association	0.400	2
TMEM252	physical association	0.400	1
CD8B	association	0.350	2
BMP1	association	0.350	1
CIDEC	association	0.350	1
FCER1A	association	0.350	1
FN1	association	0.350	1
FUBP3	association	0.350	1
GDF11	association	0.350	1
POTEF	association	0.350	1

BioGRID (40 interactions; top human partners by supporting records): GSTT1 (Affinity Capture-MS; 2 records), SLC35A2 (Affinity Capture-MS; 2 records), ARSK (Affinity Capture-MS), BMP1 (Affinity Capture-MS), BTBD1 (Affinity Capture-MS), CD8B (Affinity Capture-MS), CIDEC (Affinity Capture-MS), CSN1S1 (Biochemical Activity), DKK2 (Affinity Capture-MS), EZH2 (Affinity Capture-MS), FBXO42 (Proximity Label-MS), FCER1A (Affinity Capture-MS), FN1 (Affinity Capture-MS), FUBP3 (Affinity Capture-MS), GDF11 (Affinity Capture-MS)

SIGNOR signaling

showing 1 of 2 signaling interactions:

A	Effect	B	Mechanism
PRSS2	“up-regulates activity”	F2RL1	cleavage

Disease & clinical

Genetic variants

Variant evidence for PRSS2: 2 ClinVar records (0 pathogenic / likely pathogenic); 1 GWAS association.

ClinVar

2 variants total. Per-class counts are floors (≥ shown; pagination cap):

Classification	Count (floor)
Pathogenic	0
Likely pathogenic	0
Uncertain significance	0
Likely benign	0
Benign	0

SpliceAI

Top 10 splice-impact sites by Δscore (adjacent positions with the same effect merged into one range; 23 predictions of 225):

Position(s)	Effect	Δscore	Sites
7:142772047–142772048	acceptor_loss	1.0000	6
7:142773520–142773521	donor_loss	1.0000	2
7:142773907	acceptor_gain	1.0000
7:142773916	acceptor_gain	1.0000
7:142773917–142773918	acceptor_loss	1.0000	6
7:142773995	donor_gain	1.0000
7:142774036	donor_gain	1.0000
7:142772037	acceptor_gain	0.9900
7:142772043	acceptor_gain	0.9900
7:142773520–142773521	donor_loss	0.9900	3

AlphaMissense

758 missense substitutions predicted likely pathogenic (of 1,607 scored), across 191 residues. Top 20 hotspot residues, ranked by the number of likely-pathogenic substitutions (of those reachable by a single-nucleotide change), then by mean score:

Residue	Likely-pathogenic substitutions	Mean am_pathogenicity	Max am_pathogenicity
M183	9	0.920	0.975
D107	8	0.997	0.999
D199	8	0.995	0.999
D194	8	0.991	0.998
H63	8	0.981	0.994
H46	8	0.930	0.967
H96	8	0.875	0.988
W144	7	0.997	1.000
C196	7	0.996	0.998
C48	7	0.994	0.998
C64	7	0.994	0.998
C185	7	0.994	0.998
C220	7	0.993	0.998
C171	7	0.992	0.998
W238	7	0.991	0.999
W57	7	0.984	0.998
C30	7	0.982	0.993
W216	7	0.981	0.997
C160	7	0.971	0.991
F47	7	0.879	0.981

HPA cancer prognostics

RNA cancer specificity: Cancer enriched (Pancreatic Adenocarcinoma)

Human Protein Atlas survival analysis — favorable = higher expression predicts better survival.

1 prognostic cancer types:

Cancer	Prognostic	p-value
Uterine Corpus Endometrial Carcinoma (TCGA)	unfavorable	0.000119

Disease associations

OMIM: gene MIM:601564 | disease phenotypes:

HPO phenotypes

17 phenotypes (HPO-id order):

HPO	Term
HP:0000006	Autosomal dominant inheritance
HP:0000819	Diabetes mellitus
HP:0000952	Jaundice
HP:0001733	Pancreatitis
HP:0001738	Exocrine pancreatic insufficiency
HP:0001945	Fever
HP:0001974	Increased total leukocyte count
HP:0001977	Abnormal thrombosis
HP:0002027	Abdominal pain
HP:0002202	Pleural effusion
HP:0002570	Steatorrhea
HP:0005206	Pancreatic pseudocyst
HP:0005213	Pancreatic calcification
HP:0011227	Elevated circulating C-reactive protein concentration
HP:0012379	Abnormal circulating enzyme concentration or activity
HP:0030247	Splanchnic vein thrombosis
HP:0100027	Recurrent pancreatitis

GWAS associations

1 associations:

Study	Trait	p-value
GCST001741_1	Pancreatitis	2e-14

Drugs & pharmacology

Drug and pharmacology data

Is drug target: yes

ChEMBL targets (3): CHEMBL2095204 (PROTEIN FAMILY), CHEMBL2096988 (SELECTIVITY GROUP), CHEMBL3159 (SINGLE PROTEIN)

Molecules with ChEMBL bioactivity

Phase ≥1, by development phase (incl. off-target/promiscuous compounds). Patent mentions across the top 20 by phase: 174,410 (via chembl_molecule»patent_compound — counts attach to the compound, not the gene–compound relationship, so off-target/promiscuous molecules can dominate).

12 molecules by phase:

Molecule	Name	Phase	Patents
CHEMBL1166	ARGATROBAN	4	233
CHEMBL5189739	BEROTRALSTAT	4	7
CHEMBL266349	MELAGATRAN	4	5,456
CHEMBL338802	SULFAGUANIDINE	4	4,993
CHEMBL590799	CAMOSTAT	3	6,825
CHEMBL48361	DABIGATRAN	3	13,643
CHEMBL4112929	MILVEXIAN	3	142
CHEMBL50	QUERCETIN	3	75,572
CHEMBL226335	RUTIN	3	58,533
CHEMBL9509	SILIBININ	3	132
CHEMBL8260	BAICALEIN	2	8,718
CHEMBL114586	SEPIMOSTAT	2	156

PharmGKB: 1 entry (CPIC guideline: no)

GtoPdb / IUPHAR curated pharmacology

(IUPHAR/BPS Guide to Pharmacology — expert-curated)

Target class: enzyme — S1: Chymotrypsin

Binding affinities (BindingDB)

574 measured of 707 human assays (761 total across all organisms); most potent 50 below. Values come from heterogeneous assays and are not directly comparable.

Ligand	Measure	Value	Patent
2-(3-Carbamimidoyl-phenyl)-5-trifluoromethyl-2H-pyrazole-3-carboxylic acid [5-(2-sulfamoyl-phenyl)-pyrimidin-2-yl]-amide	KI	0.001 nM
2-(3-Carbamimidoyl-phenyl)-5-methyl-2H-pyrazole-3-carboxylic acid (3-fluoro-2’-sulfamoyl-biphenyl-4-yl)-amide	KI	0.005 nM
2-(3-Carbamimidoyl-phenyl)-5-methyl-2H-pyrazole-3-carboxylic acid [5-(2-sulfamoyl-phenyl)-pyridin-2-yl]-amide	KI	0.007 nM
2-(3-Carbamimidoyl-phenyl)-5-methyl-2H-pyrazole-3-carboxylic acid (2’-methanesulfonyl-biphenyl-4-yl)-amide	KI	0.008 nM
2-(3-Carbamimidoyl-phenyl)-5-trifluoromethyl-2H-pyrazole-3-carboxylic acid (2’-methanesulfonyl-biphenyl-4-yl)-amide	KI	0.008 nM
2-(3-Carbamimidoyl-phenyl)-5-methyl-2H-pyrazole-3-carboxylic acid (3-chloro-2’-sulfamoyl-biphenyl-4-yl)-amide	KI	0.009 nM
2-(3-Carbamimidoyl-phenyl)-5-trifluoromethyl-2H-pyrazole-3-carboxylic acid [5-(2-sulfamoyl-phenyl)-pyridin-2-yl]-amide	KI	0.009 nM
2-(3-Carbamimidoyl-phenyl)-5-methyl-2H-pyrazole-3-carboxylic acid (3-bromo-2’-sulfamoyl-biphenyl-4-yl)-amide	KI	0.01 nM
2-(3-Carbamimidoyl-phenyl)-5-trifluoromethyl-2H-pyrazole-3-carboxylic acid (2’-sulfamoyl-biphenyl-4-yl)-amide	KI	0.015 nM
3-(3-Carbamimidoyl-phenyl)-3H-[1,2,3]triazole-4-carboxylic acid (2’-sulfamoyl-biphenyl-4-yl)-amide; TFA	KI	0.023 nM
1-(3-Carbamimidoyl-phenyl)-1H-tetrazole-5-carboxylic acid (2’-sulfamoyl-biphenyl-4-yl)-amide; TFA	KI	0.037 nM
2-(3-Carbamimidoyl-phenyl)-5-methyl-2H-pyrazole-3-carboxylic acid (2’-trifluoromethyl-biphenyl-4-yl)-amide	KI	0.04 nM
N-(5-chloro-2-ethylcarbamoylmethoxy-benzyl)-2-(6-methyl-2-oxo-3-phenylmethanesulfonylamino-2H-pyridin-1-yl)-acetamide	KI	0.04 nM
2-(3-Carbamimidoyl-phenyl)-5-methyl-2H-pyrazole-3-carboxylic acid [5-(2-sulfamoyl-phenyl)-pyrimidin-2-yl]-amide	KI	0.041 nM
N-(6-Amino-2-methyl-pyridin-3-ylmethyl)-2-[3-(2,2-difluoro-2-pyridin-2-yl-ethylamino)-6-methyl-2-oxo-2H-pyrazin-1-yl]-acetamide	KI	0.042 nM
5-Butyl-2-(3-carbamimidoyl-phenyl)-2H-pyrazole-3-carboxylic acid (2’-sulfamoyl-biphenyl-4-yl)-amide; TFA	KI	0.06 nM
N-(5-Chloro-2-ethylcarbamoylmethoxy-benzyl)-2-(6-methyl-2-oxo-3-phenethylamino-2H-pyrazin-1-yl)-acetamide	KI	0.07 nM
4-(3-Carbamimidoyl-phenyl)-2-methyl-thiazole-5-carboxylic acid (2’-sulfamoyl-biphenyl-4-yl)-amide; TFA	KI	0.08 nM
1-[3-(Aminomethyl)phenyl]-N-[3-fluoro-2-(methylsulfonyl)-[1,1-biphenyl]-4-yl]-3-(trifluoromethyl)-1H-pyrazole-5-carboxamide	KI	0.15 nM
3-(3-Carbamimidoyl-phenyl)-isoxazole-4-carboxylic acid (2’-sulfamoyl-biphenyl-4-yl)-amide	KI	0.15 nM
2-(3-Carbamimidoyl-phenyl)-2H-pyrazole-3-carboxylic acid (2’-sulfamoyl-biphenyl-4-yl)-amide; TFA	KI	0.16 nM
3-(3-Carbamimidoyl-phenyl)-1-methyl-1H-pyrazole-4-carboxylic acid (2’-sulfamoyl-biphenyl-4-yl)-amide; TFA	KI	0.2 nM
4-Bromo-1-(3-carbamimidoyl-phenyl)-1H-pyrrole-2-carboxylic acid (2’-sulfamoyl-biphenyl-4-yl)-amide; TFA	KI	0.29 nM
1-(3-Carbamimidoyl-phenyl)-4-methyl-1H-imidazole-2-carboxylic acid (2’-sulfamoyl-biphenyl-4-yl)-amide; TFA	KI	0.3 nM
3-chloro-N-{2-[(4-chlorophenyl)carbamoyl]-4-methylphenyl}-1-benzothiophene-2-carboxamide	KI	0.32 nM
1-(3-Carbamimidoyl-phenyl)-1H-imidazole-2-carboxylic acid (2’-sulfamoyl-biphenyl-4-yl)-amide; TFA	KI	0.33 nM
4-(3-Carbamimidoyl-phenyl)-2-methyl-oxazole-5-carboxylic acid (2’-sulfamoyl-biphenyl-4-yl)-amide; TFA	KI	0.4 nM
2-(3-Carbamimidoyl-phenyl)-5-methyl-2H-pyrazole-3-carboxylic acid (2’-fluoro-biphenyl-4-yl)-amide	KI	0.46 nM
CHEMBL147645	KI	0.46 nM
CHEMBL6192325	IC50	0.49 nM
2-(1-Methyl-1H-imidazol-2-yl)ethyl 3-[(5-chlorothiophene-2-carbonyl)amino]-N-{2-ethyl-3-[(3S)-3-hydroxy-2-oxopyrrolidin-1-yl]benzene-1-sulfonyl}-S-alaninate hydrochloride	IC50	0.49 nM	US-20230391761: SUBSTITUTED S-ALANINATE DERIVATIVES
L-374087	KI	0.5 nM
3-chloro-N-{4-chloro-2-[(4-chlorophenyl)carbamoyl]phenyl}-1-benzothiophene-2-carboxamide	KI	0.6 nM
1-(3-Carbamimidoyl-phenyl)-1H-pyrrole-2-carboxylic acid (2’-sulfamoyl-biphenyl-4-yl)-amide; TFA	KI	0.8 nM
CHEMBL5189562	KI	0.8 nM
4-(3-Carbamimidoyl-phenyl)-thiazole-5-carboxylic acid (2’-sulfamoyl-biphenyl-4-yl)-amide; TFA	KI	0.82 nM
2-(3-Aminomethyl-phenyl)-5-trifluoromethyl-2H-pyrazole-3-carboxylic acid (3-fluoro-2’-sulfamoyl-biphenyl-4-yl)-amide	KI	0.91 nM
CHEMBL6192725	IC50	0.91 nM
CHEMBL3398615	KI	1 nM
2-(3-Carbamimidoyl-phenyl)-N-(2’-sulfamoyl-biphenyl-4-yl)-nicotinamide; TFA	KI	1 nM
CHEMBL6189853	IC50	1 nM
3-(3-Carbamimidoyl-phenyl)-3H-imidazole-4-carboxylic acid (2’-sulfamoyl-biphenyl-4-yl)-amide; TFA	KI	1.1 nM
CHEMBL3398614	KI	1.2 nM
2-(3-Aminomethyl-phenyl)-5-methyl-2H-pyrazole-3-carboxylic acid (3-fluoro-2’-methanesulfonyl-biphenyl-4-yl)-amide	KI	1.2 nM
2-[6-Methyl-2-oxo-3-(2-pyridin-2-yl-ethylamino)-2H-pyrazin-1-yl]-N-(1H-pyrrolo[2,3-c]pyridin-5-ylmethyl)-acetamide	KI	1.2 nM
[2-(5-Chloro-2-[1,2,4]triazol-1-yl-benzyl)-oxazolo[4,5-c]pyridin-4-yl]-(2,2-difluoro-2-piperidin-2-yl-ethyl)-amine	KI	1.2 nM
2-(3-Carbamimidoyl-phenyl)-5-methyl-2H-pyrazole-3-carboxylic acid biphenyl-4-ylamide	KI	1.3 nM
CHEMBL3808801	KI	1.3 nM
CHEMBL3809909	KI	1.4 nM
CHEMBL3359576	IC50	1.5 nM

ChEMBL bioactivities

803 potent at pChembl≥5 of 927 total, top 50 by pChembl (potency: 10 = 0.1 nM, 6 = 1 µM).

pChembl	Type	Value	Unit	Molecule
10.52	Ki	0.03	nM	CHEMBL3623792
10.00	Ki	0.1	nM	CHEMBL239127
10.00	Ki	0.1	nM	CHEMBL453539
9.85	IC50	0.14	nM	CHEMBL3980104
9.85	IC50	0.14	nM	CHEMBL3917451
9.80	Ki	0.16	nM	CHEMBL3623793
9.80	Ki	0.16	nM	CHEMBL4483694
9.77	IC50	0.17	nM	CHEMBL3947949
9.77	IC50	0.17	nM	CHEMBL3985298
9.77	IC50	0.17	nM	CHEMBL3972244
9.77	IC50	0.17	nM	CHEMBL3909962
9.74	IC50	0.18	nM	CHEMBL3961130
9.72	IC50	0.19	nM	CHEMBL3951207
9.72	IC50	0.19	nM	CHEMBL3897484
9.72	IC50	0.19	nM	CHEMBL3939171
9.72	IC50	0.19	nM	CHEMBL3969953
9.70	IC50	0.2	nM	CHEMBL3977211
9.68	IC50	0.21	nM	CHEMBL3940399
9.68	IC50	0.21	nM	CHEMBL3917451
9.66	IC50	0.22	nM	CHEMBL3971081
9.64	IC50	0.23	nM	CHEMBL4109828
9.62	IC50	0.24	nM	CHEMBL3953763
9.60	IC50	0.25	nM	CHEMBL3933667
9.59	IC50	0.26	nM	CHEMBL3947460
9.57	IC50	0.27	nM	CHEMBL3962586
9.55	IC50	0.28	nM	CHEMBL4113549
9.55	IC50	0.28	nM	CHEMBL3893507
9.55	IC50	0.28	nM	CHEMBL3893474
9.52	Ki	0.3	nM	CHEMBL2419745
9.52	IC50	0.3	nM	CHEMBL3957994
9.52	IC50	0.3	nM	CHEMBL4106875
9.52	Ki	0.3	nM	CHEMBL420540
9.51	IC50	0.31	nM	CHEMBL3922459
9.51	IC50	0.31	nM	CHEMBL3941889
9.47	IC50	0.34	nM	CHEMBL3977663
9.47	IC50	0.34	nM	CHEMBL3963997
9.46	IC50	0.35	nM	CHEMBL3940716
9.42	IC50	0.38	nM	CHEMBL3962513
9.42	IC50	0.38	nM	CHEMBL3912722
9.41	IC50	0.39	nM	CHEMBL3925221
9.41	IC50	0.39	nM	CHEMBL3941734
9.41	IC50	0.39	nM	CHEMBL3955210
9.40	IC50	0.4	nM	CHEMBL3964583
9.39	IC50	0.41	nM	CHEMBL3985101
9.36	IC50	0.44	nM	CHEMBL3916887
9.35	IC50	0.45	nM	CHEMBL3926197
9.35	IC50	0.45	nM	CHEMBL3940894
9.35	IC50	0.45	nM	CHEMBL3967403
9.35	IC50	0.45	nM	CHEMBL3929693
9.34	IC50	0.46	nM	CHEMBL3979741

PubChem BioAssay actives

745 with measured affinity, of 2206 total; 50 most potent distinct compounds. Largely complementary to BindingDB; screening values are coarse (µM, 4 dp), so sub-nM hits tie at the floor.

Compound	Assay	Type	Value	Unit
(1R,4S,7S,13S,19S,22S,25S,28S,31R,34S,41S,44S,50S)-50-benzyl-4,19-bis[(2S)-butan-2-yl]-25,34-bis[3-(diaminomethylideneamino)propyl]-28-[(1R)-1-hydroxyethyl]-22-(hydroxymethyl)-3,6,12,18,21,24,27,30,33,36,39,43,49,52-tetradecaoxo-54,55-dithia-2,5,11,17,20,23,26,29,32,35,38,42,48,51-tetradecazapentacyclo[29.21.4.07,11.013,17.044,48]hexapentacontane-41-carboxylic acid	1251573: Inhibition of beta-trypsin (unknown origin) using Bz-FVRpNA substrate by spectrophotometry method	ki	<0.0001	uM
2-[(1R,3aS,7S,10S,13S,16S,19S,22S,25R,28S,31S,34S,37S,40S,43R,49S,55S,58R,61S,64R,67S,73S,79S,82R,88S,94S,97S)-10,19,22-tris(4-aminobutyl)-73-(2-amino-2-oxoethyl)-13,61-bis[(2S)-butan-2-yl]-28,31,67-tris(3-carbamimidamidopropyl)-40,97-bis(carboxymethyl)-37,88,94-tris(hydroxymethyl)-79-[(4-hydroxyphenyl)methyl]-55-methyl-16-(2-methylpropyl)-1a,2,4a,8,11,14,17,20,23,26,29,32,35,38,41,44,50,53,56,59,62,65,68,71,74,77,80,83,86,89,92,95,98-tritriacontaoxo-3a-propan-2-yl-7a,8a,11a,12a,15a,16a-hexathia-2a,3,5a,9,12,15,18,21,24,27,30,33,36,39,42,45,51,54,57,60,63,66,69,72,75,78,81,84,87,90,93,96,99-tritriacontazahexacyclo[56.47.4.425,64.443,82.03,7.045,49]heptadecahectan-34-yl]acetic acid	1533293: Inhibition of trypsin (unknown origin)	ki	<0.0001	uM
2-[(1R,4S,7S,13S,19S,22S,25S,28S,31R,34S,40S,43S,49S)-25-(4-aminobutyl)-49-benzyl-4,19-bis[(2S)-butan-2-yl]-34-[3-(diaminomethylideneamino)propyl]-28-[(1R)-1-hydroxyethyl]-22-(hydroxymethyl)-3,6,12,18,21,24,27,30,33,36,39,42,48,51-tetradecaoxo-53,54-dithia-2,5,11,17,20,23,26,29,32,35,38,41,47,50-tetradecazapentacyclo[29.20.4.07,11.013,17.043,47]pentapentacontan-40-yl]acetic acid	1251580: Inhibition of trypsin (unknown origin)	ki	0.0001	uM
2-[(1R,4S,7S,13S,19S,22S,25S,28S,31R,34S,40S,43R,49S)-25-(4-aminobutyl)-49-benzyl-4,19-bis[(2S)-butan-2-yl]-34-[3-(diaminomethylideneamino)propyl]-28-[(1R)-1-hydroxyethyl]-22-(hydroxymethyl)-3,6,12,18,21,24,27,30,33,36,39,42,48,51-tetradecaoxo-53,54-dithia-2,5,11,17,20,23,26,29,32,35,38,41,47,50-tetradecazapentacyclo[29.20.4.07,11.013,17.043,47]pentapentacontan-40-yl]acetic acid	218709: Compound was tested for inhibition of Sunflower beta-trypsin	ki	0.0001	uM
(1R,4S,7S,13S,19S,22S,25S,28S,31R,34S,41S,44S,50S)-50-benzyl-4-[(2S)-butan-2-yl]-25,34-bis[3-(diaminomethylideneamino)propyl]-28-[(1R)-1-hydroxyethyl]-22-(hydroxymethyl)-19-[(4-hydroxyphenyl)methyl]-3,6,12,18,21,24,27,30,33,36,39,43,49,52-tetradecaoxo-54,55-dithia-2,5,11,17,20,23,26,29,32,35,38,42,48,51-tetradecazapentacyclo[29.21.4.07,11.013,17.044,48]hexapentacontane-41-carboxylic acid	1251573: Inhibition of beta-trypsin (unknown origin) using Bz-FVRpNA substrate by spectrophotometry method	ki	0.0002	uM
(2S)-2-[[(2S)-2-[[2-[[(2S)-2-[[2-[[(1S,6S,12S,15S,18S,21S,24S,27S,30R,33S,36S,39S,42S,45S,48R,53S,56S,62S,68S,71R,74S,79S,85S)-6-[[(2S)-2-[[2-[(2-aminoacetyl)amino]acetyl]amino]-3-methylbutanoyl]amino]-15,24,27-tris(4-aminobutyl)-62-(2-amino-2-oxoethyl)-18,74-bis[(2S)-butan-2-yl]-33,36,68-tris(3-carbamimidamidopropyl)-39,45-bis(carboxymethyl)-42-(hydroxymethyl)-56-[(4-hydroxyphenyl)methyl]-79-methyl-21-(2-methylpropyl)-7,13,16,19,22,25,28,31,34,37,40,43,46,55,58,61,64,67,70,73,76,78,81,84,90-pentacosaoxo-3,4,50,51,92,93-hexathia-8,14,17,20,23,26,29,32,35,38,41,44,47,54,57,60,63,66,69,72,75,77,80,83,89-pentacosazapentacyclo[46.28.14.430,71.08,12.085,89]tetranonacontane-53-carbonyl]amino]acetyl]amino]-3-hydroxypropanoyl]amino]acetyl]amino]-3-hydroxypropanoyl]amino]butanedioic acid	1628817: Inhibition of trypsin (unknown origin) using Bz-FVRpNA as substrate incubated for 30 mins measured for 7 mins by morrison plot analysis	ki	0.0002	uM
2-[[(2S)-1-[(2S)-2-[(5-carbamimidoylthiophen-2-yl)methylcarbamoyl]pyrrolidin-1-yl]-1-oxo-3,3-diphenylpropan-2-yl]amino]acetic acid	766527: Inhibition of human trypsin	ki	0.0003	uM
2-[[(2R)-1-[(2S)-2-[(5-carbamimidoylthiophen-2-yl)methylcarbamoyl]pyrrolidin-1-yl]-1-oxo-3,3-diphenylpropan-2-yl]amino]acetic acid	215245: In vitro inhibition constant (Ki) against human trypsin was determined	ki	0.0003	uM
2-[2-[2-[[2-[[5-chloro-2-(1,2,4-triazol-1-yl)phenyl]methyl]-[1,3]oxazolo[4,5-c]pyridin-4-yl]amino]ethyl]piperidin-1-yl]acetic acid	254278: Inhibitory constant against trypsin	ki	0.0007	uM
2-[(1R,4S,7S,13S,19S,22S,25S,28S,31R,34S,40S,43S,49S)-49-(2-amino-2-oxoethyl)-4,19-bis[(2S)-butan-2-yl]-25-[3-(diaminomethylideneamino)propyl]-28,34-bis[(1R)-1-hydroxyethyl]-22-(hydroxymethyl)-3,6,12,18,21,24,27,30,33,36,39,42,48,51-tetradecaoxo-53,54-dithia-2,5,11,17,20,23,26,29,32,35,38,41,47,50-tetradecazapentacyclo[29.20.4.07,11.013,17.043,47]pentapentacontan-40-yl]acetamide	1251580: Inhibition of trypsin (unknown origin)	ki	0.0007	uM
[2-[(3,5-dimethyl-1-phenylpyrazol-4-yl)amino]-2-oxoethyl] 2-(6-carbamimidoyl-2-methyl-1H-indol-3-yl)acetate	1387138: Inhibition of trypsin (unknown origin) pre-incubated for 30 mins before N-Boc-FSR-AMC substrate addition and measured after 30 mins	ic50	0.0010	uM
(2S)-2-[[(2S)-2-amino-5-(diaminomethylideneamino)pentanoyl]amino]-N-[(2S)-1-[[(2S)-1-(1,3-benzothiazol-2-yl)-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-1-oxopropan-2-yl]pentanediamide	682988: Tight binding inhibition of human trypsin expressed in Drosophila melanogaster S2 cells using Boc-QAR-AMC as substrate incubated for 15 mins prior to substrate addition measured for 30 mins by fluorimetric analysis	ki	0.0010	uM
ethyl 2-[2-[2-[[2-[[5-chloro-2-(1,2,4-triazol-1-yl)phenyl]methyl]-[1,3]oxazolo[4,5-c]pyridin-4-yl]amino]ethyl]piperidin-1-yl]acetate	254278: Inhibitory constant against trypsin	ki	0.0013	uM
[4-(diaminomethylideneamino)phenyl] 4-(diaminomethylideneamino)benzoate	1555462: Inhibition of trypsin (unknown origin) using Boc-Val-Pro-Arg-AMC as substrate preincubated with enzyme for 15 mins followed by addition of substrate by fluorescence plate reader analysis	ic50	0.0014	uM
N-[2-(1-benzylpiperidin-2-yl)ethyl]-2-[[5-chloro-2-(1,2,4-triazol-1-yl)phenyl]methyl]-[1,3]oxazolo[4,5-c]pyridin-4-amine	254278: Inhibitory constant against trypsin	ki	0.0015	uM
2-[[5-chloro-2-(1,2,4-triazol-1-yl)phenyl]methyl]-N-(2,2-difluoro-2-piperidin-2-ylethyl)-[1,3]oxazolo[4,5-c]pyridin-4-amine	254278: Inhibitory constant against trypsin	ki	0.0015	uM
2-[2-[2-[[2-[[5-chloro-2-(1,2,4-triazol-1-yl)phenyl]methyl]-[1,3]oxazolo[4,5-c]pyridin-4-yl]amino]ethyl]piperidin-1-yl]ethanol	254278: Inhibitory constant against trypsin	ki	0.0016	uM
2-[[(2R)-1-[(2S)-2-[(5-carbamimidoylthiophen-2-yl)methylcarbamoyl]-2,5-dihydropyrrol-1-yl]-3-cyclohexyl-1-oxopropan-2-yl]amino]acetic acid	264686: Inhibition of trypsin	ic50	0.0016	uM
[4-(aminomethyl)phenyl] 4-(diaminomethylideneamino)benzoate	1555462: Inhibition of trypsin (unknown origin) using Boc-Val-Pro-Arg-AMC as substrate preincubated with enzyme for 15 mins followed by addition of substrate by fluorescence plate reader analysis	ic50	0.0016	uM
2-[[5-chloro-2-(1,2,4-triazol-1-yl)phenyl]methyl]-N-(2-piperidin-2-ylethyl)-[1,3]oxazolo[4,5-c]pyridin-4-amine	254278: Inhibitory constant against trypsin	ki	0.0016	uM
2-[[(2R)-1-[(2S)-2-[(4-carbamimidoylfuran-2-yl)methylcarbamoyl]-2,5-dihydropyrrol-1-yl]-3-cyclohexyl-1-oxopropan-2-yl]amino]acetic acid	264686: Inhibition of trypsin	ic50	0.0019	uM
(2S)-N-[(2S)-1-(1,3-benzoxazol-2-yl)-5-(diaminomethylideneamino)-1-oxopentan-2-yl]-1-[(2R)-2-(3,3-dimethylbutanoylamino)-3-phenylpropanoyl]pyrrolidine-2-carboxamide;2,2,2-trifluoroacetic acid	321200: Inhibition of human trypsin	ic50	0.0023	uM
4-[2-[(2S,11S)-11-(2,3-dihydro-1-benzofuran-5-ylsulfonylamino)-12-oxo-1-azatricyclo[6.4.1.04,13]trideca-4,6,8(13)-trien-2-yl]-2-oxoethyl]piperidine-1-carboximidamide	215553: Inhibitory constant against trypsin determined in Vitro	ki	0.0025	uM
[4-(diaminomethylideneamino)phenyl] 4-aminobenzoate	1555462: Inhibition of trypsin (unknown origin) using Boc-Val-Pro-Arg-AMC as substrate preincubated with enzyme for 15 mins followed by addition of substrate by fluorescence plate reader analysis	ic50	0.0028	uM
2-[[5-chloro-2-(1,2,4-triazol-1-yl)phenyl]methyl]-N-[2-[1-(2,2-difluoroethyl)piperidin-2-yl]ethyl]-[1,3]oxazolo[4,5-c]pyridin-4-amine	254278: Inhibitory constant against trypsin	ki	0.0029	uM
4-[3-[(3S)-3-(2,3-dihydro-1-benzofuran-5-ylsulfonylamino)-2-oxoazepan-1-yl]-2-oxopropyl]benzenecarboximidamide	215553: Inhibitory constant against trypsin determined in Vitro	ki	0.0032	uM
1-(3-carbamimidoylphenyl)-N-[2-fluoro-4-(2-methylsulfonylphenyl)phenyl]-3-(trifluoromethyl)pyrazole-5-carboxamide	215244: In vitro activity against human trypsin.	ki	0.0034	uM
3-(3-carbamimidoylphenyl)-N-[4-(2-sulfamoylphenyl)phenyl]triazole-4-carboxamide;2,2,2-trifluoroacetic acid	215413: Binding affinity towards human trypsin	ki	0.0034	uM
[4-[2-[2-(dimethylamino)-2-oxoethoxy]-2-oxoethyl]phenyl] 4-(diaminomethylideneamino)benzoate	1555462: Inhibition of trypsin (unknown origin) using Boc-Val-Pro-Arg-AMC as substrate preincubated with enzyme for 15 mins followed by addition of substrate by fluorescence plate reader analysis	ic50	0.0035	uM
3-[[(2R)-1-[[(2S)-3-[3-(aminomethyl)phenyl]-1-[(4-carbamimidoylphenyl)methylamino]-1-oxopropan-2-yl]amino]-1-oxo-5-phenylpentan-2-yl]sulfamoylmethyl]benzoic acid	1626146: Inhibition of trypsin (unknown origin)	ki	0.0036	uM
benzyl N-[(2S)-6-amino-1-[5-[[4-[4-[(2-fluorophenyl)methyl]piperazine-1-carbonyl]phenyl]methyl]-1,2,4-oxadiazol-3-yl]-1-oxohexan-2-yl]carbamate	269676: Inhibition of human trypsin	ki	0.0037	uM
1-(3-carbamimidoylphenyl)-N-[4-(2-sulfamoylphenyl)phenyl]-3-(trifluoromethyl)pyrazole-5-carboxamide	215244: In vitro activity against human trypsin.	ki	0.0039	uM
1-(3-carbamimidoylphenyl)-N-[2-fluoro-4-(2-sulfamoylphenyl)phenyl]-3-(trifluoromethyl)pyrazole-5-carboxamide	215244: In vitro activity against human trypsin.	ki	0.0040	uM
1-(3-carbamimidoylphenyl)-N-[4-(2-methylsulfonylphenyl)phenyl]-3-(trifluoromethyl)pyrazole-5-carboxamide	215244: In vitro activity against human trypsin.	ki	0.0043	uM
2-[[(1R)-2-[(2S)-2-[(4-carbamimidoylphenyl)methylcarbamoyl]azetidin-1-yl]-1-cyclohexyl-2-oxoethyl]amino]acetic acid	766527: Inhibition of human trypsin	ki	0.0043	uM
2-(3-carbamimidoylphenyl)-N-[2-fluoro-4-(2-sulfamoylphenyl)phenyl]-5-methylpyrazole-3-carboxamide	215244: In vitro activity against human trypsin.	ki	0.0046	uM
2-[[(2R)-1-[(2S)-2-[(6-carbamimidoyl-3-pyridinyl)methylcarbamoyl]-2,5-dihydropyrrol-1-yl]-3-cyclohexyl-1-oxopropan-2-yl]amino]acetic acid	264686: Inhibition of trypsin	ic50	0.0048	uM
5-[3-[(3S)-3-(2,3-dihydro-1-benzofuran-5-ylsulfonylamino)-2-oxoazepan-1-yl]-2-oxopropyl]thiophene-2-carboximidamide	215553: Inhibitory constant against trypsin determined in Vitro	ki	0.0059	uM
(2S,4R)-1-acetyl-N-[1-(1,3-benzothiazol-2-yl)-5-(diaminomethylideneamino)-1-oxopentan-2-yl]-4-hydroxypyrrolidine-2-carboxamide	320964: Inhibition of human trypsin by chromogenic assay	ki	0.0060	uM
(2R)-2-(benzylsulfonylamino)-N-[2-[(4-carbamimidoylphenyl)methylamino]-2-oxoethyl]-4-(1-oxidopyridin-1-ium-2-yl)butanamide	290692: Inhibition of trypsin	ki	0.0063	uM
1-(3-carbamimidoylphenyl)-N-[4-(2-sulfamoylphenyl)phenyl]tetrazole-5-carboxamide;2,2,2-trifluoroacetic acid	215413: Binding affinity towards human trypsin	ki	0.0064	uM
2-[[5-chloro-2-(1,2,4-triazol-1-yl)phenyl]methyl]-N-[2-[1-(2,2,2-trifluoroethyl)piperidin-2-yl]ethyl]-[1,3]oxazolo[4,5-c]pyridin-4-amine	254278: Inhibitory constant against trypsin	ki	0.0069	uM
(2S)-2-[[(2S)-2-[[2-[[(2S)-2-[[2-[[(1R,4S,7S,10S,13S,16S,19R,22S,25S,28S,31S,34S,37S,40S,45S,48S,51R,54S,60S,66S,69S,79S,85S)-40-[[(2S)-5-amino-2-[[2-[(2-aminoacetyl)amino]acetyl]amino]-5-oxopentanoyl]amino]-22,25-bis(4-aminobutyl)-60-(2-amino-2-oxoethyl)-37-benzyl-31,48-bis[(2S)-butan-2-yl]-13,16,34,54-tetrakis(3-carbamimidamidopropyl)-4,10-bis(carboxymethyl)-7-(hydroxymethyl)-66-[(4-hydroxyphenyl)methyl]-85-methyl-28-(2-methylpropyl)-3,6,9,12,15,18,21,24,27,30,33,36,39,46,49,52,55,58,61,64,67,74,80,83,86-pentacosaoxo-42,43,71,72,89,90-hexathia-2,5,8,11,14,17,20,23,26,29,32,35,38,47,50,53,56,59,62,65,68,75,81,84,87-pentacosazatetracyclo[43.28.14.419,51.075,79]hennonacontane-69-carbonyl]amino]acetyl]amino]-3-hydroxypropanoyl]amino]acetyl]amino]-3-hydroxypropanoyl]amino]butanedioic acid	1628817: Inhibition of trypsin (unknown origin) using Bz-FVRpNA as substrate incubated for 30 mins measured for 7 mins by morrison plot analysis	ki	0.0069	uM
2-[(aR,1R,3aS,4S,10S,16R,19S,22S,25S,28S,31S,34R,37S,40S,43S,46S,49S,52S,55R,58S,67S,70S,76S,82R,85S,91S,97S)-97-(4-aminobutyl)-91-(2-amino-2-oxoethyl)-28,31,37,40,52-pentakis(3-amino-3-oxopropyl)-58-benzyl-3a,46-bis[(2S)-butan-2-yl]-49-(3-carbamimidamidopropyl)-19,67-bis(carboxymethyl)-22,70,76-tris(hydroxymethyl)-85-[(4-hydroxyphenyl)methyl]-4-methyl-43-(2-methylpropyl)-2a,3,5a,6,9,15,18,21,24,27,30,33,36,39,42,45,48,51,54,57,60,63,66,69,72,75,78,81,84,87,90,93,96,99-tetratriacontaoxo-7a,8a,11a,12a,15a,16a-hexathia-1a,2,4a,5,8,14,17,20,23,26,29,32,35,38,41,44,47,50,53,56,59,62,65,68,71,74,77,80,83,86,89,92,95,98-tetratriacontazapentacyclo[53.50.4.416,82.434,100.010,14]heptadecahectan-25-yl]acetic acid	1533299: Inhibition of trypsin (unknown origin) using Bz-FVR-pNA as substrate preincubated for 30 mins followed by substrate addition and measured for 7 mins by spectrophotometric method	ki	0.0069	uM
2-[2-[(6R,6aR,11bR)-2-carbamimidoyl-6,6a,7,11b-tetrahydro-5H-indeno[2,1-c]quinolin-6-yl]-5-hydroxy-4-methoxyphenyl]benzoic acid	760605: Inhibition of purified human trypsin	ki	0.0075	uM
4-[3-[(3S)-3-(2,3-dihydro-1-benzofuran-5-ylsulfonylamino)-2-oxoazepan-1-yl]-2-oxopropyl]-3-fluorobenzenecarboximidamide	215553: Inhibitory constant against trypsin determined in Vitro	ki	0.0076	uM
(2S)-2-[[(3S,9S,12S,15S,18S,21R,26R,29S,32S)-21-[[(2S)-2-[(2-aminoacetyl)amino]-5-(diaminomethylideneamino)pentanoyl]amino]-15-(4-aminobutyl)-9-[(2S)-butan-2-yl]-29-[3-(diaminomethylideneamino)propyl]-18-[(1R)-1-hydroxyethyl]-12-(hydroxymethyl)-2,8,11,14,17,20,28,31-octaoxo-23,24-dithia-1,7,10,13,16,19,27,30-octazatricyclo[30.3.0.03,7]pentatriacontane-26-carbonyl]amino]-3-(1H-imidazol-5-yl)propanoic acid	1251573: Inhibition of beta-trypsin (unknown origin) using Bz-FVRpNA substrate by spectrophotometry method	ki	0.0080	uM
4-[3-[(3S)-3-(benzenesulfonamido)-2-oxoazepan-1-yl]-2-oxopropyl]benzenecarboximidamide	215553: Inhibitory constant against trypsin determined in Vitro	ki	0.0083	uM
N-[2-[(5-chloro-2-pyridinyl)carbamoyl]-4-methoxyphenyl]-5-methyl-6,7-dihydro-4H-[1,3]thiazolo[5,4-c]pyridine-2-carboxamide	1585403: Inhibition of human trypsin preincubated for 30 mins followed by substrate addition and measured for 20 mins	ic50	0.0091	uM
3-butyl-1-(3-carbamimidoylphenyl)-N-[4-(2-sulfamoylphenyl)phenyl]pyrazole-5-carboxamide;2,2,2-trifluoroacetic acid	215244: In vitro activity against human trypsin.	ki	0.0110	uM

CTD chemical–gene interactions

28 total (human), top 28 by PubMed support.

Chemical	Actions (top 5)	PubMed papers
Nickel	decreases reaction, affects expression, increases expression	2
Phenylmercuric Acetate	affects cotreatment, increases expression	2
sodium arsenate	decreases expression, increases abundance	1
terbufos	increases methylation	1
trichostatin A	affects expression, decreases reaction	1
cobaltous chloride	increases expression	1
butyraldehyde	increases expression	1
mercuric bromide	affects cotreatment, increases expression	1
S 1 (combination)	increases response to substance	1
vandetanib	increases expression	1
4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide	affects cotreatment, increases expression	1
perfluorohexanesulfonic acid	affects expression	1
dorsomorphin	affects cotreatment, increases expression	1
Bortezomib	decreases expression	1
Temozolomide	decreases expression	1
Arsenic Trioxide	affects expression	1
Arbutin	decreases expression	1
Arsenic	decreases expression, increases abundance	1
Atrazine	decreases expression	1
Fonofos	increases methylation	1
Endosulfan	increases expression	1
Estradiol	decreases expression	1
Fluorouracil	affects expression	1
Parathion	increases methylation	1
Silicon Dioxide	decreases expression	1
Tretinoin	decreases expression	1
Aflatoxin B1	increases methylation	1
Okadaic Acid	decreases expression	1

ChEMBL screening assays

386 unique, capped per target: 335 binding, 51 admet

Representative assays (with source publication via chembl_document):

Assay ID	Type	Description	Source paper
CHEMBL1006751	Binding	Inhibition of trypsin-induced elevation in PAI1 production in HUVEC by ELISA	Effects of flavonoids isolated from scutellariae radix on fibrinolytic system induced by trypsin in human umbilical vein endothelial cells. — *J Nat Prod*
CHEMBL4320630	ADMET	Stability of the compound assessed as trypsin (unknown origin)-mediated compound hydrolysis after 8 hrs by SDS-PAGE analysis	Antimicrobial Peptides with High Proteolytic Resistance for Combating Gram-Negative Bacteria. — *J Med Chem*

Clinical trials (associated diseases)

Via MONDO — disease-level, not drug-specific.

Predicted chemistry — Sugi Predict

The predicted patent-compound landscape for PRSS2 across ~30M SureChEMBL compounds — explore on Sugi Predict.